TW202228678A - 依達拉奉經口投予用醫藥組成物及其投予方法 - Google Patents
依達拉奉經口投予用醫藥組成物及其投予方法 Download PDFInfo
- Publication number
- TW202228678A TW202228678A TW110142253A TW110142253A TW202228678A TW 202228678 A TW202228678 A TW 202228678A TW 110142253 A TW110142253 A TW 110142253A TW 110142253 A TW110142253 A TW 110142253A TW 202228678 A TW202228678 A TW 202228678A
- Authority
- TW
- Taiwan
- Prior art keywords
- administration
- edaravone
- pharmaceutical composition
- hours
- meal
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020188514 | 2020-11-12 | ||
| JP2020-188514 | 2020-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202228678A true TW202228678A (zh) | 2022-08-01 |
Family
ID=81602356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110142253A TW202228678A (zh) | 2020-11-12 | 2021-11-12 | 依達拉奉經口投予用醫藥組成物及其投予方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11911366B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245303A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JPWO2022102737A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230098267A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116761601A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124062A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021380319B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198014A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228678A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022102737A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024036261A2 (en) * | 2022-08-10 | 2024-02-15 | Kpr U.S., Llc | Occlusion detection system and method for a flow control apparatus |
| EP4559463A1 (en) * | 2023-11-23 | 2025-05-28 | Ferrer Internacional, S.A. | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| CN109125261B (zh) * | 2016-03-16 | 2021-11-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| EP3785703A1 (en) * | 2017-01-17 | 2021-03-03 | Treeway TW001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
| BR112021008197A2 (pt) | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| JP7012792B2 (ja) | 2020-08-06 | 2022-01-28 | 株式会社 ディー・エヌ・エー | 動画を配信するためのシステム、方法、及びプログラム |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
-
2021
- 2021-11-12 JP JP2022562195A patent/JPWO2022102737A1/ja active Pending
- 2021-11-12 AR ARP210103147A patent/AR124062A1/es unknown
- 2021-11-12 AU AU2021380319A patent/AU2021380319B2/en active Active
- 2021-11-12 CN CN202180075839.XA patent/CN116761601A/zh active Pending
- 2021-11-12 EP EP21891982.7A patent/EP4245303A4/en active Pending
- 2021-11-12 CA CA3198014A patent/CA3198014A1/en active Pending
- 2021-11-12 TW TW110142253A patent/TW202228678A/zh unknown
- 2021-11-12 KR KR1020237017986A patent/KR20230098267A/ko not_active Ceased
- 2021-11-12 WO PCT/JP2021/041673 patent/WO2022102737A1/ja not_active Ceased
- 2021-11-12 IL IL302533A patent/IL302533A/en unknown
- 2021-12-29 US US17/564,538 patent/US11911366B2/en active Active
-
2023
- 2023-12-28 US US18/398,241 patent/US12478611B2/en active Active
-
2025
- 2025-01-07 JP JP2025002313A patent/JP2025061070A/ja active Pending
- 2025-05-22 AU AU2025203773A patent/AU2025203773A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12478611B2 (en) | 2025-11-25 |
| US20220142982A1 (en) | 2022-05-12 |
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| AU2021380319B2 (en) | 2025-03-20 |
| IL302533A (en) | 2023-07-01 |
| US11911366B2 (en) | 2024-02-27 |
| CN116761601A (zh) | 2023-09-15 |
| AU2025203773A1 (en) | 2025-06-12 |
| WO2022102737A1 (ja) | 2022-05-19 |
| KR20230098267A (ko) | 2023-07-03 |
| US20240173297A1 (en) | 2024-05-30 |
| AR124062A1 (es) | 2023-02-08 |
| EP4245303A4 (en) | 2024-10-09 |
| CA3198014A1 (en) | 2022-05-19 |
| EP4245303A1 (en) | 2023-09-20 |
| JP2025061070A (ja) | 2025-04-10 |
| AU2021380319A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3731870B1 (en) | Liquid oral formulations for pde v inhibitors | |
| JP2025061070A (ja) | エダラボン経口投与用医薬組成物およびその投与方法 | |
| RU2668882C2 (ru) | Жидкая фармацевтическая композиция | |
| EA019881B1 (ru) | Стабилизированная суспензия каризбамата для применения в педиатрии | |
| US12458593B2 (en) | Suspensions and diluents for metronidazole and baclofen | |
| US12527769B2 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| CN114761002A (zh) | 用于奥美拉唑混悬剂的组合物和试剂盒 | |
| JPWO2014061808A1 (ja) | 胃ろう栄養患者用栄養組成物 | |
| JP6157928B2 (ja) | 肝臓への脂肪蓄積抑制剤 | |
| EP2668851B1 (en) | Liver function-improving agent | |
| JP6856813B1 (ja) | 亜鉛点滴静注用製剤 | |
| US10973886B2 (en) | Use of a pharmaceutical composition containing at least one digestive enzyme in artificial feeding | |
| US20190060266A1 (en) | Pharmaceutical compositions of tiopronin and methods for preparing thereof | |
| KR20250099117A (ko) | 도파민을 포함하는 약학적 주사용액 |